BioCentury | Jan 8, 2021

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

Carlyle leads Abbisko’s $123M series DShanghai-based oncology company Abbisko Therapeutics Co. Ltd. raised $123 million in a series D round led by the Carlyle Group. The company named Warburg Pincus, OrbiMed, Lake Bleu Capital and an...
BioCentury | Dec 4, 2020
Product Development

AZ’s opportunity to expand the severe asthma market with tezepelumab

Phase III data from AstraZeneca and Amgen’s tezepelumab suggests the mAb could substantially expand the use of biologics in severe asthma beyond the subset of patients addressed by marketed therapies....
BioCentury | Sep 24, 2020

Sept. 23 Quick Takes: Zai raises $776M, Silverback $85M; plus Novartis, PureTech, UCB and more

Zai prices Hong Kong offering, becomes dual-listedCross-border in-licensing company Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) raised HK$5.9 billion ($776.1 million) via an offering that will land it on the Hong Kong stock exchange. The deal’s combined...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

This is the third article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
BioCentury | Aug 27, 2020
Distillery Therapeutics

IL-25 to mitigate GvHD in the GI tract after transplant

DISEASE CATEGORY: Transplant INDICATION: Graft-versus-host disease (GvHD) IL-25 could protect against gastrointestinal GvHD by reducing the loss of goblet cells, which contribute to barrier function through mucus and antimicrobial peptide production. In patients who had...
BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline

As Gilead continues to expand its manufacturing capabilities for Veklury, the company has moved a step closer to gaining full approval of the therapy in the U.S. for COVID-19. The company announced its NDA submission for...
BioCentury | May 19, 2020
Emerging Company Profile

Helmed by OrbiMed’s Wang, Inmagene debuts with Phase II autoimmune program

...has shown “a good safety profile,” said Wang. Several antibodies against IL-17A or its receptor IL17R...
...raised: $20 million Investors: Undisclosed CEO: Jonathan Wang Patents: Undisclosed Targets IL-17A - Interleukin-17A IL17R (IL17RA...
BioCentury | Apr 24, 2020
Product Development

Upbeat Lilly earnings come with positive psoriasis results, delays for two autoimmune programs

Lilly announced positive Phase III data for autoimmune disease candidate mirikizumab and attributed a bump in revenue, adjusted guidance and trial delays to the COVID-19 pandemic. As part of its 1Q20 earnings, Eli Lilly and...
BioCentury | Mar 31, 2020

Lilly gains rights to Sitryx’s two most advanced immunometabolic programs in four-target deal

For its first pharma partnership, U.K.-based Sitryx is granting Lilly rights to its two most advanced immunometabolism programs in exchange for upfront cash and an equity investment totaling $60 million -- twice the amount of...
BioCentury | Jan 11, 2020
Targets & Mechanisms

Colitis-associated somatic mutations yield new colorectal cancer target

Kyoto University team identifies colitis-associated somatic mutations that are lost in colitis-associated cancer to reveal a new colorectal cancer target. A Japanese team has identified novel colorectal cancer targets by contrasting somatic mutations in cancerous...
Items per page:
1 - 10 of 413